Milk thistle benefits: what the research does and doesn't show

The evidence doesn't support milk thistle as a treatment for any liver or kidney disease, and there's no trial in a general, healthy population at all. What does exist is a set of small-to-mid-sized trials in people already diagnosed with a liver or kidney condition, with mixed, generally modest results — not the sweeping "detox" and "liver health" reputation the plant has in supplement marketing.

What the evidence doesn't support

It doesn't support milk thistle, silymarin, or silibinin as a treatment for fatty liver disease, hepatitis, cirrhosis, kidney disease or any other diagnosed condition. It doesn't support taking it as a general "liver detox" or a way to protect the liver from alcohol, medication or everyday wear — nobody has tested milk thistle that way, in people without an existing diagnosis. Every trial below recruited people who already had a liver or kidney condition and were already under a doctor's care for it; none of them tested milk thistle as something a healthy person takes preventively. None of it describes a specific brand's dose or product, and nothing here is a claim about any product.

What the trials found

A 2017 systematic review and meta-analysis in World Journal of Gastroenterology searched for every randomized trial of oral silymarin in adults with a diagnosed liver disease, published through January 2016. Seventeen trials qualified for the systematic review and six had comparable enough data to pool. Across those six, silymarin produced a statistically significant drop in ALT (0.26 IU/mL) and AST (0.53 IU/mL) compared with control — but the authors themselves describe that drop as too small to be clinically meaningful, and gamma-GT didn't change significantly at all. The trials they reviewed varied widely in dose, extract and duration, the overall quality was rated low, and the studies disagreed with each other more than a consistent effect would predict.

A more recent 2024 meta-analysis in Annals of Hepatology pooled 26 randomized trials, 2,375 people, all with nonalcoholic fatty liver disease (NAFLD) or its more advanced form, NASH. This one found more: reductions in total cholesterol, triglycerides, LDL, fasting insulin, ALT and AST, an increase in HDL, and — in a subset of trials that examined liver biopsies — improved hepatic steatosis on histology. That's a considerably more positive result than the 2017 review — the difference is a larger, more homogeneous set of NAFLD-specific trials — but the authors still conclude the effects need confirming in further, better-designed research, and none of the pooled trials used people without an existing fatty liver diagnosis.

On the kidney side, two small randomized trials in people with type 2 diabetes and diagnosed diabetic kidney disease reached different conclusions. A 2012 placebo-controlled trial gave 60 people with diabetic nephropathy and heavy protein loss in their urine 420 mg of silymarin a day (three 140 mg doses) for three months, on top of their usual blood-pressure medication, and found a significantly larger drop in urine albumin (a marker of kidney damage) in the silymarin group, and urinary markers of inflammation and oxidative stress were also lower in that group than in the placebo group. A larger 2017 trial in 102 people with the same underlying condition, run for longer, found no significant difference between silymarin and placebo in kidney function decline, dialysis need or death — the two studies' outcomes don't agree, and the dose used in the 2017 trial wasn't reported in its published summary.

A separate limitation runs under all of the above: a 2021 systematic review of silymarin's pharmacokinetics found that its flavonolignans have low oral bioavailability. The body rapidly conjugates them in the gut and liver and pumps a large share of what's left back into the intestine, so a meaningful amount of an oral dose may never reach the bloodstream intact. That doesn't mean the trials above are wrong, but it's a real, unresolved question about how a pill-form dose relates to the concentrations that produced results in a lab.

Trial	Population	Dose	Result
de Avelar 2017 (6 pooled trials)	Adults with diagnosed liver disease	Varied across trials	Small ALT/AST drop, authors say not clinically meaningful
Li 2024 (26 pooled trials)	Adults with NAFLD/NASH	Varied across trials	Improved lipids, ALT/AST, and biopsy-confirmed steatosis in a subset
Fallahzadeh 2012 (n=60)	Type 2 diabetes with diabetic nephropathy	420 mg/day silymarin, 3 months	Larger drop in urine albumin vs. placebo
Voroneanu 2017 (n=102)	Type 2 diabetes with diabetic nephropathy	Not reported in the published abstract	No significant difference in kidney outcomes vs. placebo

Questions people ask

Is milk thistle good for your liver?

The honest answer is mixed, and every trial that exists was in people already diagnosed with a liver condition. A 2017 pooled analysis of six trials found a statistically significant but clinically negligible drop in liver enzymes; a larger 2024 pooled analysis focused specifically on fatty liver disease found more substantial improvements, including on biopsy in a subset of trials. Neither trial tested a general, healthy population, and neither is about a specific product's dose.

Does milk thistle help kidneys?

Not reliably. Two small randomized trials in people with diabetic kidney disease found opposite results — one found a benefit on a urine-protein marker, the larger one found no difference in actual kidney function outcomes. There's no trial of milk thistle for kidney health in people without a diagnosed kidney condition.

Is milk thistle good for kidneys and liver at the same time?

The trials that exist tested one organ system at a time, in people already diagnosed with a disease in that organ — there's no trial measuring both together, and no trial in someone without either diagnosis.

Is milk thistle good for pancreatitis or Hashimoto's?

No trial we found tested milk thistle for either. Silymarin's studied uses are concentrated on the liver and, to a lesser extent, diabetic kidney disease — pancreatitis and thyroid autoimmune conditions aren't part of that literature.

Does milk thistle help with hangovers or alcohol?

No clinical trial has tested milk thistle for hangover prevention or for protecting the liver during or after drinking in otherwise healthy people. The liver-disease trials above studied people with a diagnosed condition, not occasional drinkers, so they don't speak to that use.

Is milk thistle good for skin, hair or energy?

We found no clinical trial testing milk thistle for skin, hair growth or energy levels. Those uses don't appear in the research reviewed here.

When to talk to a doctor

Anyone with a diagnosed liver or kidney condition — including fatty liver disease, hepatitis, cirrhosis or diabetic kidney disease — should manage it with a doctor, and should not start or substitute milk thistle for a prescribed treatment without medical guidance. The trials above were run alongside, not instead of, standard medical care. If you're pregnant, nursing, or take any prescription medication, ask a doctor before adding milk thistle — some of the research above found real, if inconsistent, effects on drug-metabolizing enzymes, covered in milk thistle and medications: what to check.

Related reading: what is milk thistle, how much milk thistle should you take a day, and who should not take milk thistle.